Skip to content

Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma

Phase II Study of Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01025076
Enrollment
14
Registered
2009-12-03
Start date
2009-02-28
Completion date
2012-05-31
Last updated
2017-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Keywords

Enlarged gastric pouch and stoma, Post bariatric surgery

Brief summary

Executive Summary Aims and Hypotheses of the Study: The aim of the study will be to evaluate the safety, effectiveness and early outcome of the StomaphyX procedure for reducing the enlarged gastric pouch and stoma in post-bariatric patients. The study will test a hypothesis that the StomaphyX procedure will be effective in promoting the loss of regained weight, reducing the risk for comorbidities and improving patients' quality of life. Type of Study: Prospective non-randomized Study Duration: 12 months Number of Patients: 20 Inclusion Criteria: 18-70 years of age, BMI ≥ 35, ≥ 2 years after primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy. Pts also demonstrate a weight regain of 15% of excess body weight loss. Exclusion Criteria: Esophageal stricture, or any anatomic conditions that preclude passage of transoral endoluminal instruments, has another causal factor for weight regain other than stoma or pouch dilatation, portal hypertension, coagulation disorders or chronic use of anticoagulants, any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk to the patient. Intervention Treatment: Creation of multiple full-thickness plications within the gastric pouch using the StomaphyX device (EndoGastric Solutions, Inc., Redmond, WA, USA) Evaluation Criteria Primary Outcome: Change in body weight at 6 and 12 months Secondary Outcome: Gastric pouch volume assessment, stoma diameter determination, quality of life scores, waist circumference, co-morbidity resolution Effectiveness and Safety Assessment Clinical: Weight, height, waist circumference quality of life questionnaires (Impact of Weight QOL-Lite, Eating and Weight Patterns, Three-factor Eating, Emotional Eating Scale, GI QoL, GSRS and/or PGWB) Anatomical: Upper GI endoscopy, computed tomography or barium radiography Biochemical: Blood and urine tests (glucose, cholesterol, triglyceride, HDL, LDL, uric acid) Safety: Adverse events, complications, co-morbidities, hospital stay

Interventions

DEVICEStomaphyX

StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.

Sponsors

Alberta Health services
CollaboratorOTHER
University of Alberta
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70 years * BMI 35 or greater with one or more comorbidities * At least 2 years post-Roux-en-Y gastric bypass surgery * At enrollment, has regained at least 15% of excess body weight loss * Enlarged Stoma Diameter * Enlarged gastric pouch * Completed successful nutritional screening and compliant with nutritional programs * Completed successful cardiopulmonary evaluation * Patient willing to cooperate with follow-up assessment tests * Signed informed consent

Exclusion criteria

* Esophageal stricture or any anatomic conditions that preclude passage of transoral endoluminal instruments * Has another causal factor for weight regain other than stoma or pouch dilatation such as non compliant with nutritional and exercise programs * Portal hypertension * Coagulation disorders or chronic use of anticoagulants * Any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk to the patient

Design outcomes

Primary

MeasureTime frameDescription
Primary Outcome: Change in Body WeightAt 6 months comparing to baseline weightBody weight changes at 6 months after StomaphyX procedure comparing to baseline weight.

Countries

Canada

Participant flow

Participants by arm

ArmCount
StomaphX
Patients with weight gain following VBG had endoluminal pouch reduction performed using the StomaphyXTM device in revisional bariatric surgery clinic
14
Total14

Baseline characteristics

CharacteristicStomaphX
Age, Continuous46.4 years
STANDARD_DEVIATION 6.7
Pre-operative weight119.5 Kg
STANDARD_DEVIATION 25.9
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
3 / 14
serious
Total, serious adverse events
0 / 14

Outcome results

Primary

Primary Outcome: Change in Body Weight

Body weight changes at 6 months after StomaphyX procedure comparing to baseline weight.

Time frame: At 6 months comparing to baseline weight

ArmMeasureValue (MEAN)Dispersion
StomaphXPrimary Outcome: Change in Body Weight9.6 kgStandard Deviation 7.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026